Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Google Secures Pentagon AI Deal for Classified Projects 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
WALTHAM, Mass., May 01, 2017 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Deutsche Bank 42nd Annual Health Care Conference in Boston on Thursday, May 4, 2017 at 9:20 a.m. ET.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon is currently enrolling patients in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit www.proteontx.com.
Investor Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
[email protected]
Media Contact
Ann Stanesa, Ten Bridge Communications
617-230-0347
[email protected]
